Challenge in diabetes therapy: Effects of thiazolidinediones beyond blood glucose control;Herausforderung Diabetestherapie: Effekte der Glitazone jenseits der Blutzuckerkontrolle

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 18, 2009, Pages 949-954

  Schernthaner, G ^a,b   Forst, T ^a   Gulba, D ^a   Haberbosch, W ^a   Hanefeld, M ^a   Linss C ^a   Marz W ^a   Mehnert, H ^a   Rosak, C ^a   Schnell, O ^a   Seufert, J ^a   Tschope D ^a   Erdmann, E ^a  

^a Institutsangaben Am Ende der Arbeit ^*

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Cardiovascular risk; Comorbidities; Evidence; Insulin; Oral antidiabetic drugs; Pioglitazone; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; BUFORMIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TROGLITAZONE; VILDAGLIPTIN; VOGLIBOSE;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; IMPLANTATION; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RESTENOSIS; REVIEW; STENT; ALBUMINURIA; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; EDEMA; EVIDENCE BASED MEDICINE; FRACTURE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; INSULIN RESISTANCE; KIDNEY FAILURE; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EDEMA; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY; STROKE; THIAZOLIDINEDIONES;

EID: 65349177067     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1220255     Document Type: Review

References (81)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood- glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
2. Fachinformation actos 2007
3. Fachinformation AVANDIA 2008
4. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419
5. Bakris G, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12
6. Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur HeartJ 2008; 29: 969-983
7. Caraballo PJ, Heit JA, Atkinson EJ et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159:1750-1756
8. Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: A prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23: 392-399
9. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494
10. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164: 2097-2104
11. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660
12. Davidson M, Meyer PM, Haffher S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid inti- ma-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117:2123-2130
13. Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-2464
14. Derosa G, Cicero AF, Dangelo A et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924
15. Derosa G, DAngelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383
16. Derosa G, Fogari E, Cicero AF et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007; 30: 387-394
17. Derosa G, Gaddi AV, Piccinni MN et al. Antithrombotic effects of rosiglita- zone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005; 25: 637-645
18. Dortnandy JA, Charbonnel B, Eckland DJ et al Secondary prevention of ma- crovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289
19. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
20. Erdmann E. Herzinsuffizienz unter Glitazonen - was wissen wir heute? Dtsch Med Wochenschr 2009; 134:154-158
21. Erdmann E, Dormandy J A, Charbonnel B, et al., The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49:1772-1780
22. Erdmann E, Hanefeld M. Glitazone - eine antidiabetische Substanzklasse aus kardiologischer Sicht. Dtsch Arztebl 2004; 101: A 2954-A 2961
23. Eurich DT, McAlister FA Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335:497-
24. Forst T, Karagiannis E, Lubben G et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008; 197: 311- 317
25. Forst T, PfutznerA, Lubben G et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 2007; 56:491-496
26. Geng DF, Jin DM, Wu W et al. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials. Atherosclerosis 2008; 202: 521-528
27. Gerstein HC, Miller ME Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
28. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glyce- mic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554
29. Haffher SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684
30. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147 (Pubitemid 38196723)
31. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39:1577-1583
32. Hanefeld M, Marx N, Pfutzner A et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297
33. Holman RR Paul SK, Bethel MA, Matthews DR Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
34. Home PD, Pocock SJ Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38
35. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vase Biol 1997; 17: 1114-1120
36. Kahn SE Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
37. Koro CE Bowlin SJ Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 2005; 14: 697-703
38. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136
39. Langenfeld MR Forst T, Hohberg C et al. Pioglitazone decreases carotid in- tima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111:2525-2531
40. Lebovitz HE, Dole JF, Patwardhan R Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
41. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188
42. Margolis DJ Hoffstad O, Strom BL Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepi- demiol Drug Saf 2008; 17: 753-759
43. Martens EM, Visseren FL, de Koning EJ, RabeUnk TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778
44. Maru S, Koch GG, Stender M., et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005; 28: 20-26
45. Marx N, Froehlkh J Siam L et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vase Biol 2003; 23: 283-288
46. Marx N, Wohrle J Nusser T et al. Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792- 2798
47. Matthews DR Charbonnel BH, Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167-174 (Pubitemid 40467663)
48. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006; 296: 2572-2581
49. Mohanty P, Aljada A, Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-2735
50. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203
51. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263
52. Nichols GA, Koro CE, Gullion CM et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005;21:51-57
53. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29:101-106
54. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005; 96: 61F-68F
55. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556-1565
56. Nissen SE Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573
57. Nissen SE Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080 (Pubitemid 38541684)
58. Nissen SE Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 (Pubitemid 46919772)
59. Patel A MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572
60. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931
61. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678
62. Raz I Wilson PW, Strqjek K et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-386
63. Rejnmark L, Vestergaard P, Mosekilde L Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 2007; 118: 338-344
64. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70:1223-1233
65. Scherbaum W, Ritz E. Prevention und Therapie der diabetischen Nephro- pathie. Dtsch Arztebl 2005; 102: A137-143
66. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009; submitted in press
67. Schernthaner G, Matthews DR Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068- 6076
68. Schneider CA, Ferrannini E, Defronzo R et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19:182-187
69. Singh S, Lake YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195
70. Sourij H, Zweiker R Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006; 29: 1039-1045
71. Souverein PC Webb DJ, Weil JG et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66: 1318-1324
72. Sowers JR Lester MA Diabetes and cardiovascular disease. Diabetes Care 1999; 22 Suppl 3: C14-C20
73. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macro- vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
74. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 2007; 76: 12-17
75. Takagi T, Yamamuro A, Tamita K et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am HeartJ 2003; 146: E5-
76. Targownik IE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-326
77. Turner RC Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828
78. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45: 1330-1337 (Pubitemid 39470036)
79. Wilcox R Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macro Vascular Events 04). Stroke 2007; 38: 865-873
80. Wilcox R Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155: 712-717
81. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953